Post-traumatic stress disorder (PTSD) is a debilitating condition leading to significant personal and societal burden. Standard treatments frequently demonstrate limited efficacy, leading to persistent symptoms and high dropout rates. Psilocybin has shown promise in treating depression, a condition that is often comorbid with PTSD. We aimed to explore participant experiences of psilocybin...
CureusDecember 1, 2025Paweł Liszka, Agata Ogórek, Klaudia M Olejnik-Chlewicka et al.
Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry as potential therapeutic tools. The aim of this paper is to review current data on their mechanisms of action, clinical applications in the treatment of mood and anxiety disorders, addictions and post-traumatic stress disorder (PTSD), as well as to...
Zusammenfassung: Hintergrund: Die Schweizerische Gesellschaft für Suchtmedizin (SSAM) setzt sich für die wissenschaftlich fundierte und patientenorientierte Behandlung von Suchterkrankungen ein. Position: Angesichts der jüngsten wissenschaftlichen Erkenntnisse und internationaler Entwicklungen beurteilt die SSAM Psychedelika assistierte Psychotherapie (PAT) mit klassischen Psychedelika wie LSD...
Abstract Early maladaptive schemas (EMS) are highly prevalent in patients seeking psychedelic-assisted psychotherapy and correlate strongly with baseline depression and anxiety. This study characterized EMS in 192 adults and longitudinally followed 74 patients receiving psilocybin- or LSD-assisted therapy. We found that baseline schema burden, particularly related to failure and defectiveness,...
Abstract Background Recent studies have highlighted the neuroprotective properties of certain mushrooms. Proposing a research hypothesis for a novel field of study into mitigating the neurological and neuropsychological symptoms associated with Alzheimer's disease (AD) and possible cure with natural methods. Psilocybe cubensis and Hericium erinaceus have proven to show therapeutic effects for...
Alzheimer s & DementiaDecember 1, 2025Danielle Bukovsky, Aron Amaev, Jianmeng Song et al.
Abstract Background Amnestic mild cognitive impairment (aMCI) is characterized by synaptic loss and cognitive decline and is considered a precursor to Alzheimer’s Disease. Currently, there are no effective treatments for aMCI, and available treatments (i.e., cholinesterase inhibitors) do not appear to improve cognitive or functional outcomes. Psychedelics, including psilocybin, have regained...
ABSTRACT The psychedelic psilocybin has gained popularity in recent years as a therapy for treatment‐resistant depression and has been reported to reduce symptoms of depression and anxiety. Psilocybin's active metabolite, psilocin, possesses a binding affinity for serotonin receptors as well as for the serotonin transporter (5‐HTT). We recently reported that in contrast to wild‐type mice,...
Alzheimer s & DementiaDecember 1, 2025Leelavathi N. Madhu, Yogish Somayaji, Sanya Kotian et al.
Abstract Background Chronic neuroinflammation plays a significant role in Alzheimer’s disease (AD) pathogenesis associated with a decline in cognitive and mood function. Currently, there are no effective therapies to alleviate the progression of brain dysfunction in AD. Psilocybin, an FDA‐approved drug for treating major depressive disorder, can restrain neuroinflammation and improve...
Zusammenfassung: Hintergrund: In der Schweiz kann Psilocybin im Rahmen von Ausnahmebewilligungen therapeutisch genutzt werden. Programm: Die Klinik Südhang entwickelte basierend auf Evidenz und Ethik ein standardisiertes Programm für Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen. Das quartalsweise durchgeführte Programm umfasst Diagnostik, mehrere Einzel- und...
Depression is a debilitating mental disorder affecting millions worldwide, yet current pharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs), often exhibit delayed onset and limited efficacy. The chronic social defeat (CSD) stress model in mice is a well-established preclinical paradigm for inducing depression-like behaviors and evaluating antidepressants...
Psychedelics, such as psilocybin, reorganise large-scale brain connectivity, yet how these changes are reflected across electrophysiological (electroencephalogram, EEG) and haemodynamic (functional magnetic resonance imaging, fMRI) networks remains unclear. We present Brain-MGF, a multimodal graph fusion network for joint EEG-fMRI connectivity analysis. For each modality, we construct graphs...
PAP was associated with modest, short-term improvements in performance on measures of processing speed and executive function among individuals with TRD. While these changes appeared independent of mood, they did not consistently exceed expected practice effects. These findings highlight the need for adequately powered, controlled trials to clarify whether observed cognitive changes reflect...
Psilocybin alters perception and brain dynamics. Here, we investigate the effects of psilocybin using psychophysics, ultra-high field functional MRI, and computational modeling. We find that psilocybin alters contextual perception in the Ebbinghaus illusion, as well as contextual modulation in cortical responses to visual stimuli. We propose a computational model capable of capturing and...
Abstract This study explores the first-time use of psychedelic macrodoses among Latin American adults, addressing a gap in the literature regarding naturalistic use outside clinical settings. A total of 4,810 participants from six Latin American countries completed an online survey assessing sociodemographic characteristics, substances used, consumption contexts, motivations, and subjective...
Abstract Disorders of consciousness (DoC), including unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS), have limited treatment options and are characterized by low complexity of brain activity. Recent research suggests that psychedelic drugs, which enhance the complexity of brain activity, could offer promising therapies. Here, individualized whole‐brain computational...
Emerging evidence suggests that classical psychedelics may offer therapeutic potential for opioid use disorder (OUD) by alleviating key hallmarks such as altered reward processing and dependence. However, the mechanisms behind these effects remain unclear. Our data demonstrate that a single administration of the psychedelic psilocybin (PSI) reduces conditioned behavior and withdrawal induced by...
Medical SciencesNovember 20, 2025Silvia Natoli, Arturo Cuomo, Maurizio Marchesini et al.
Background: Chronic pain affects nearly one in five adults worldwide and remains a major healthcare burden due to its persistence, multidimensional impact, and resistance to conventional therapies. The opioid crisis has further highlighted the urgent need for safer and more effective alternatives. Psilocybin, a serotonergic psychedelic compound, has re-emerged as a potential therapeutic option...
Stroke remains a leading cause of death and long-term disability and stroke patients have only limited treatment options.Recent preclinical evidence suggests that psychedelics such as psilocybin may confer cerebroprotection by engaging serotonin (5-HT) receptor pathways, yet their cellular targets and translational potential remain poorly understood.Here, we propose to systematically evaluate...
Abstract Natural variation in psilocybin content across mushroom samples presents a significant challenge to consistent dosing in both research and retreat settings. In this observational report, we describe a pragmatic approach for quantifying psilocybin content in naturally sourced material to ensure more standardized dosing across participants. Eleven individuals participated in a 7-day...